Actinium Pharmaceuticals, Inc. (ATNM)
Makes cancer-fighting drugs by attaching radioactive particles to antibodies.
$0.87+0.01%Healthcare
StockGlow Score
Leaning Bearish
BearishBullish
1 year ago-46.2%
The outlook
ATNM is trading near its 52-week low and well below both its 50- and 200-day moving averages, reflecting weak near-term momentum. Analyst coverage shows a starkly divided picture: the average price target sits 477% above the current price, though the overall StockGlow score leans bearish at 21/100, suggesting meaningful skepticism despite the high targets.
What’s behind the score
Price trendBelow its 50- & 200-day averages
52-week range6% of the way from its 52-week low to high
Price targetAvg target +477% vs current price
Analyst price target
~12-month · 4 analysts$5.00average target+477.0% vs now
Now $0.87
Low $2.00High $9.00
Published targets from Wall Street analysts (public data) — what analysts expect over roughly a year. This is not a StockGlow forecast and not a recommendation. Analyst targets are frequently wrong.
Market cap
$27.2M
52-wk high
$1.81
52-wk low
$0.81
50-day avg
$1.03
200-day avg
$1.23
Trailing P/E
—